摘要
目的:观察五苓散对肝硬化门脉高压大鼠血流动力学的影响。方法:将造模成功的肝硬化门脉高压SD雄性大鼠动物模型40例随机分成肝硬化对照组、五苓散治疗组(高、中、低剂量组)、西药对照组各8例,以及正常对照组8例。肝硬化对照组,继续以常规方法饲养;五苓散治疗组,分高、中、低剂量组,加用中药五苓散灌胃,高剂量为5g/kg体重,中剂量为2.5g/kg体重,低剂量为1g/kg体重,西药对照组,用普萘洛尔灌胃,剂量为0.6mg/kg体重。治疗时间均为1个月。所有大鼠实验期间自由进食和饮水。于第10、20和30天,记录大鼠24h尿量。实验结束时用激光多普勒微循环仪进行血流动力学测定。血流动力学测定后,门静脉取血,采用放射免疫法测定肾素、醛固酮。结果:五苓散高剂量组门静脉血流量和肠系膜上动脉血流量与对照组及低、中剂量组比较,差异有显著性(P<0.05)。与西药对照组比较差异无显著性(P>0.05);五苓散高剂量组肾素、醛固酮明显低于其它各组且差异有显著性(P<0.05)。结论:五苓散具有降低肝硬化门脉高压的作用。
Objective ： To observe the effect of Wuling powder on hemodynamics in hepatic cirrhosis rats with portal hypertension （PHT）. Methods：Fifty male SD rat model cases were randomly divided into Hepatic cirrhosis control group, Wuling powder treatment group （high, medium and low dose group ）, Western medicine control group, and normal control cases （n=8）. Hepatic cirrhosis control group continued to be reared in the conventional way ; Wuling Powder treatment groups at high, medium and low dose group were treated with Wuling Powder of 5,2.5, lg/kg respectively, Western medicine control group was treated with propranolol （0.6mg/kg）. The treatment lasted 30 days. During the experiment all rats were given free eating and drinking. Record for 24h urine on 10th,20th and 30th day was made. At the end of the experiment, hemodynamics, renin, aldosterone were detected. Results ：The high dose Wuling Powder group can improve the portal blood flow and mesenteric blood flow, the effects was better than that of the control, the medium dose Wnling powder and the low dose Wuling powder groups （P〈0.05）, and there was no difference with the Western medicine control group （P〉0.05）. The high dose Wuling powder group can decrease the levels of renin and aldosterone, the effects was better than that of the other groups （ P〈0.05 ）. Conclusion ： Wuling powder can relieve the high pressure of portal vein in hepatic cirrhosis effectively.
出处
《辽宁中医药大学学报》
CAS
2012年第7期80-82,共3页
Journal of Liaoning University of Traditional Chinese Medicine
基金
广东省科技厅立项课题(87)
关键词
五苓散
肝硬化
门脉高压
血流动力
Wuling powder
hepatic cirrhosis
portal hypertension
hemodynaimcs
